The launch of combination products for the treatment of urinary tract infections is an emerging trend in the genito-urinary disorder drugs market. Competitors in the market are developing combination drugs to fight multi-drug resistant bacteria and also expanding indications for existing drugs for the treatment of genito-urinary disorders. For instance, Merck Sharp & Dohme Corp. offers ZERBAXA, a combination drug of a novel cephalosporin and a beta-lactamase inhibitor used for the ... Read more
